Modulation of P-glycoprotein ATPase Activity by Some Phytoconstituents

Phytotherapy Research

Volumn 24, Issue 3, 2010, Pages 454-458

  Najar, I A ^a   Sachin, B S ^a   Sharma, S C ^a   Satti, N K ^a   Suri, K A ^a   Johri, R K ^a  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

ATPase activity; P glycoprotein; Phytoconstituents

Indexed keywords

ACTEOSIDE; ADENOSINE TRIPHOSPHATASE; AGNUSIDE; ANDROGRAPHOLIDE; APOCYANIN; BERBERINE; CATECHIN; CHLOROGENIC ACID; GLYCOPROTEIN P; GLYCYRRHIZIC ACID; MAGNIFERIN; NEGUNDOSIDE; OLEANOLIC ACID; PICROSIDE I; PICROSIDE II; PIPERINE; PLANT MEDICINAL PRODUCT; SANTONIN; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; IN VITRO STUDY; JEJUNUM MUCOSA; MALE; NONHUMAN; RAT;

ADENOSINE TRIPHOSPHATASES; ALKALOIDS; ANIMALS; FEMALE; GLUCOSIDES; INTESTINAL MUCOSA; MALE; P-GLYCOPROTEIN; RATS; RATS, WISTAR;

RATTUS;

EID: 77349121410     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2951     Document Type: Article

References (24)

1. Al-Shawi MK, Polar MK, Omote H, Figler RA. 2003. Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein. J Biol Chem 278: 2629-2640.
2. Belliard AM, Leroy C, Banide H, Farinotti R, Lacour B. 2003. Decrease of intestinal P-glycoprotein activity by 2n-ropylquinoline, a new oral treatment for visceral leishmaniasis. Exp Parasitol 103: 51-56.
3. Brand W, Schutte ME, Williamson G et al. 2006. Flavonoid-ediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomed Pharmcother 60: 508-519.
4. Deferme S, Augustijns P. 2003. The effect of food components on the absorption of P-gp substrate: a review. J Pharm Pharmacol 55: 153-162.
5. Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV. 1997. Evidence for two non-identical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 94: 10594-10599.
6. Hamabe W, Maeda T, Fukazawa Y et al. 2006. P-glycoprotein ATPase activating effect of opioid analgesics and their P-glycoprotein-dependent anti-nociception in mice. Pharmacol Biochem Behav 85: 629-636.
7. He L, Liu GQ. 2002. Interaction of multidrug resistance reversal agents with P-glycoprotein ATPase activity on blood brain barrier. Acta Pharmacol Sin 23: 423-429.
8. Higgins CF, Gottesman MM. 1992. Is the multidrug transporter a flippase? Trends Biochem Sci 17: 18-21.
9. Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. 1998. Functional expression of human P-glycoprotein from plasmids using vaccinia virus-bacteriophage T7 RNA polymerase system. Meth Enzymol 33: 456-473.
10. Ishikawa T, Hirano H, Onishi Y, Sakurai A, Tarui S. 2004. Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms - high speed screening and structure-activity relationship analyses. Drug Metab Pharmacokinet 19: 1-14.
11. Izzo AA. 2004. Herb-drug interactions: an overview of the clinical evidence. Fund Clin Pharmacol 19: 1-16.
12. Khajuria A, Gupta A, Singh S et al. 2007. Iridoid glycoside composition. US Patent Application No. 0275006 A1.
13. Kokubu N, Dalia N, Cohen D, Watanabe T. 1997. Functional modulation of ATPase of P-glycoprotein by C219, a monoclonal antibody against P-glycoprotein. Biochem Biophys Res Commun 230: 398-401.
14. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with Folin phenol reagent. J Biol Chem 193: 265-275.
15. Marchetti S, Mazzanti R, Beijnen JH, Schellens JHM. 2007. Concise review: clinical relevance of drug-drug and herb-drug interactions mediated by the ABC transporter ABCB1 (MDRI, P-glycoprotein). Oncologist 12: 927-941.
16. Pauli-Magnus C, von Richter O, Burk O et al. 2000. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharm Exp Ther 293: 376-382.
17. Prabhakar A, Gupta BD, Suri KA et al. 2004. Hepatoprotective activity of 10-O-P-hydroxybenzoyliaucubin. US Patent Application No. 20040029816 A1.
18. Prabhakar A, Gupta BD, Suri KA et al. 2007. Hepatoprotective activity of 2′-P-hydroxybenzoyl mussaenosidic acid. US Patent No. 7,259,148 B2.
19. Qazi GN, Suri OP, Bedi KL et al. 2006. Hepatoprotective agent of plant origin and a process thereof. US Patent No. 6,989,162 B2.
20. Romsicki Y, Sharom FJ. 1999. The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry 38: 6887-6896.
21. Tombline G, Holt JJ, Gannon MK et al. 2008. ATP occlusion by P-glycoprotein as a surrogate measure for drug coupling. J Biol Chem 279: 5363-5373.
22. Urbatsch IL, Sankaran B, Weber J, Senior AE. 1995. Pglycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site. J Biol Chem 270: 19383-19390.
23. Yumoto R, Murakami T, Sanemasa M, Nasu R, Nagai J, Takano M. 2001. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a pglycoprotein substrate, in rats pretreated with dexamethasone. Drug Metab Dispos 29: 145-151.
24. Zhu H-J, Wang J-S, Markowitz JS et al. 2006. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharm Exp Ther 317: 850-857.